ストックスクリーナーアプリを入手
40.22
0.30%
0.12
アフターアワーズ：
40.22
前日終値:
$40.10
開ける：
$40.18
24時間の取引高:
1.58M
Relative Volume:
0.83
時価総額：
$4.75B
収益：
$1.29B
当期純損益:
$251.00M
株価収益率:
20.37
EPS:
1.9744
ネットキャッシュフロー:
$-193.86M
1週間 パフォーマンス:
-0.72%
1か月 パフォーマンス:
-2.52%
6か月 パフォーマンス:
+13.68%
1年 パフォーマンス:
+131.15%
1日の値動き範囲:
$39.66
$40.60
1週間の範囲:
$39.66
$41.65
52週間の値動き範囲:
$19.31
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
40.22 | 4.73B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
17.25 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.41 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.03 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
525.82 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indivior Pharmaceuticals, Inc. Revenue Breakdown – DUS:E7P - TradingView
Indivior PLC (INDV) Institutional Confidence - TradingKey
Indivior Announces Date and Time for Second Quarter 2026 Financial Results and Conference Call - Quiver Quantitative
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast - The Manila Times
Indivior Leadership to Host Aug. 4 Webcast After Q2 Results - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Striking Potential with a 29.94% Upside - DirectorsTalk Interviews
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.5% -- What GF Score of 69 Tells Investors - GuruFocus
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score - ChartMill
Price to earnings forward of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares in planned trade - Stock Titan
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com - Investing.com Nigeria
INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value - Stock Titan
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
How Indivior’s Multi-Index Russell 2000 Defensive Inclusion (INDV) Has Changed Its Investment Story - simplywall.st
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
Is Indivior Pharmaceuticals (INDV) Fully Valued As Russell 2000 Index Additions Draw Buyers? - simplywall.st
Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable - MSN
Indivior Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Indivior’s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV) - Yahoo Finance
Indivior added to Russell 2000 defensive indices, shares gain visibility with US investors - ad-hoc-news.de
Does Indivior (INDV) Joining Multiple Russell 2000 Defensive Indices Recast Its Opioid-Treatment Narrative? - simplywall.st
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS: INDV) added to Russell 2000 Defensive Index - marketscreener.com
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny - Ad-hoc-news.de
INDV Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Indivior Pharmaceuticals, Inc. Actuals & Estimates (LS:A42086) - TradingView
Indivior Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INDV) - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Is Big Pharma's Patent Cliff Driving a New M&A Wave - Kavout | AI
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
E7P Forecast — Price Target — Prediction for 2027 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
Reasons Why Investors Should Consider Betting on Indivior Stock - The Globe and Mail
A42086 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Australia
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior gains new overweight at Barclays on business turnaround - MSN
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
3.50%
0.34%
大文字化:
|
ボリューム (24 時間):